Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ivonescimab + platinum-based chemotherapy
- Development stage
- Unknown
- Lead developer
- Akeso
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
Ivonescimab (AK112) is a first-in-class humanized IgG1 bispecific antibody that simultaneously targets programmed cell death protein 1 (PD-1) and vascular endothelial growth factor (VEGF). By dual-targeting these pathways, it aims to enhance anti-tumor activity through both immune checkpoint inhibition and anti-angiogenesis. This specific combination involves ivonescimab administered alongside platinum-based chemotherapy (such as cisplatin or carboplatin) for the treatment of advanced non-small cell lung cancer (NSCLC). It is particularly being investigated in patients with driver mutations (EGFR, ALK, or ROS1) who have progressed after initial targeted therapies, as well as in first-line settings for patients without driver mutations.
- Brand names
- Ivonescimab
- Other names
- PD-1/VEGF bispecific antibodyAK112 plus platinum-based chemotherapyAK-112 plus platinum-based chemotherapyAK 112 plus platinum-based chemotherapy
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)VEGFA (Vascular endothelial growth factor A)
Beyond the preview
Go deeper on ivonescimab + platinum-based chemotherapy.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ivonescimab + platinum-based chemotherapy.